More recently, the TOPAZ-1 trial led to the approval of durvalumab (an anti-PD-L1 antibody) combined with GemCis as the preferred first-line treatment for advanced or metastatic CCA, improving overall survival compared to GemCis alone (mOS: 12.9 vs. 11.3 months) [22]. The gene discussed is CD274; the disease is cholangiocarcinoma.